Document is current
Any future updates will be listed below
-
Authors
Yassin, Walid
Kromenacker, Bryan
Green, James B.
Tamminga, Carol A.
del Re, Elisabetta C.
Seif, Pegah
Xia, Cuihua
Alliey-Rodriguez, Ney
Gershon, Elliot S.
Clementz, Brett A.
Pearlson, Godfrey D.
Keedy, Sarah K.
Ivleva, Elena I.
Hill, Scott Kristian
McDowell, Jennifer E.
Keshavan, Matcheri S.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R21MH133001, MH-077851, MH-103368, MH-103366, MH-077945, MH-072767, MH-078113)
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 31 July 2025
First Online: 8 August 2025
Declarations
:
: Dr. Clementz reports being on the KyNexis SAB and the B-SNIP Diagnostics, LLC Board of Managers.Dr. McDowell reports serving on the B-SNIP Diagnostics, LLC Board of ManagersDr. Keedy reports serving on the B-SNIP Diagnostics, LLC Board of ManagersDr. Ivleva reports serving on the B-SNIP Diagnostics, LLC Board of Managers. She also served on scientific advisory boards for Janssen Scientific Affairs, LLC, Alkermes, Inc and Karuna Therapeutics.Dr. Gershon reports serving on the B-SNIP Diagnostics, LLC Board of ManagersDr. Keshavan reports serving on the B-SNIP Diagnostics, LLC Board of ManagersDr. Pearlson reports serving on the B-SNIP Diagnostics, LLC Board of ManagersDr. Tamminga reports serving on the Merck DSmB, being on the Karuna SAB and owning Karuna stock, and being on the KyNexis SAB and owning KyNexis stock, and B-SNIP Diagnostics, LLC Board of Managers.Other authors have no competing interests to declare.
